Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123

Haemonetics Corporation stocks have been trading up by 17.46 percent amid heightened optimism from strong earnings and growth outlook.

Live Update At 16:46:53 EDT: On Thursday, October 08, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 17.46%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Haemonetics Corporation has been grinding higher, and the chart finally showed a real pop. Over the last few weeks, HAE mostly chopped between $104 and $109, closing at $108–109 for many sessions. Then the latest move took the stock from a prior close near $101.71 to a high of $121 and a close at $119.47, a big range expansion that catches momentum traders’ attention.

Intraday, HAE opened near $115 and pushed as high as $121 before settling just under $120, holding most of its gains. That’s important. Strong gaps that don’t fade show real demand, not just algos flicking the tape.

Fundamentally, Haemonetics runs a high-margin medical technology business. Gross margin sits around 59%, but the profit margin is only about 7.1%. That gap tells traders the company spends heavily on operations and growth. The latest quarter delivered roughly $339.4M in revenue and $33.0M in net income, with EBITDA of about $84.6M and free cash flow around $44.4M.

HAE trades rich, with a P/E near 50 and price-to-sales around 3.5. High multiples like this demand continued earnings growth and clean execution. That’s exactly why the Citi upgrade and CSL deal matter for the next leg of the trend.

Why Traders Are Watching HAE After The Citi Upgrade

The core driver of the latest move in Haemonetics is simple: a powerful Wall Street upgrade with specific earnings math behind it. Citigroup shifted HAE from Neutral to Buy and pushed its price target to $123, well above the old $92 target and above the current analyst mean around $108.40. When a big bank not only turns bullish but plants its flag above the Street average, traders listen.

For HAE, the upgrade is tied directly to a new non-exclusive supply agreement with CSL. Citi expects earnings upside from this deal and even laid out a rule-of-thumb: each 10% share recapture from CSL adds about $0.13 to EPS. That kind of number gives momentum traders a clear narrative. If Haemonetics executes, earnings scale fast, and a premium P/E suddenly looks more reasonable.

The tape backed up the thesis. HAE shares jumped about 2.4% to roughly $108 on the news, and later price action pushed into the high teens and low $120s. Yet the initial move came on below-average volume. For short-term traders, that’s a tell. The stock reacted well, but the crowd is not fully in the trade yet. Latecomers may chase if Haemonetics confirms strength on higher volume days.

In the background, Haemonetics is still integrating Vivasure. A $6.1M milestone payment to Orchestra BioMed, for a total of $11M so far, plus up to $10M in future earnouts, shows the PerQseal Elite technology is hitting development markers. It is a cash drain near term, but it also signals that HAE is not standing still in its vascular closure niche. Combined with the CSL supply tailwind, traders see a company layering multiple growth levers at once.

Conclusion

For active traders, Haemonetics now sits at the crossroads of strong news, elevated valuation, and rising expectations. The Citi upgrade to Buy with a $123 target reframed HAE as a growth name with identifiable EPS torque from the CSL supply agreement. The idea that every 10% share win adds roughly $0.13 to EPS helps explain why the stock ripped from the low $100s into the high teens and beyond.

At the same time, Haemonetics still carries meaningful leverage, with total debt well above $1.1B, even if interest coverage near 21.8x looks comfortable. Profitability is solid but not extreme, so the market is paying up for future earnings, not current ones. The Vivasure milestone payments underscore that HAE is continuing to spend to build out its product portfolio, with potential upside tied to future revenue performance. In this kind of fast-moving setup, it’s crucial for short-term traders to avoid chasing strength blindly and instead wait for clear, high-probability patterns to emerge. As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.”

The next big checkpoint is already on the calendar: Haemonetics will release Q2 FY2027 results on 2026/11/05 and host a conference call. That’s when traders will see whether early optimism from Citigroup and the CSL deal shows up in the numbers and outlook. As Tim Sykes loves to remind his students, “The market rewards preparation, not prediction.” For HAE, that means building your thesis now, tracking volume and price into earnings, and being ready to react — not hope — when the catalyst hits.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks